On June 27, 2022 Harbour BioMed ("HBM", HKEX: 02142) reported that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the B7H4x4-1BB bispecific antibody (HBM7008), which has successfully completed the dosing of first patient in the phase I trial of HBM7008 in Australia in May 2022 and received an IND approval from China National Medical Products Administration in early June 2022 (Press release, Harbour BioMed, JUN 27, 2022, View Source [SID1234616304]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HBM7008 is generated from HBM’s unique and innovative HBICE platform. It is a first-in-class bispecific antibody targeting B7H4 and 4-1BB. The bispecific antibody can engage and activate T cells by 4-1BB only in B7H4 positive tumor microenvironment. B7H4 is overexpressed on a variety of solid malignancies, including breast, ovarian, endometrial, and non-small cell lung cancers. With its crosslinking-dependent specificity on tumors and potent immune modulation activity, HBM7008 has shown an excellent safety profile with strong anti-tumor efficacy in pre-clinical studies.
"As the first-in-class bispecific antibody targeting B7H4 and 4-1BB, HBM7008 is expected to lead the development of next-generation immunotherapeutics. With IND clearance by the FDA, we will be able to accelerate our multi-center phase I development of HBM7008," said Dr. Humphrey Gardner, CMO of Harbour BioMed.
About HBM7008
HBM7008 is a bispecific antibody targeting Tumor-Associated Antigen B7H4x4-1BB that not only displays high potency in T cell co-stimulation and tumor growth inhibition, but may also translate to better safety due to its strict dependency on TAA-mediated crosslinking T cell activation, thus mitigating toxicities such as liver toxicity seen in first generation 4-1BB agonists. HBM7008 is one of the fully human bispecific antibodies developed from the HBICE platform of the Company. It is the only bispecific antibody against these two targets globally. Its unique specificity on tumors and immune modulation activity makes it a promising therapeutic in PD-L1 negative or PD-1/PD-L1 resistant patients.